Silo Pharma Inc. (NASDAQ: SILO) announced that the United States Patent and Trademark Office has issued a Notice of Allowance for a patent application covering SPC-15, its lead intranasal therapeutic targeting post-traumatic stress disorder. The invention, titled “Compositions and Methods for the Prevention of Stress-Induced Fear, Depressive-Like and Anxiety-Like Behavior,” includes composition and method claims related to the company’s proprietary therapeutic approach to preventing or delaying stress-induced behavioral responses.
A Notice of Allowance indicates that the USPTO has completed its examination and determined that the application meets the requirements for patentability and should be granted shortly. This development marks a significant milestone for Silo Pharma, as U.S. patent protection is an important component of its strategy while it advances SPC-15 development for PTSD. The allowance adds to the company’s biopharmaceutical intellectual property portfolio of issued and allowed patents.
Earlier this year, a corresponding patent was issued by the Japan Patent Office, further solidifying Silo Pharma’s global intellectual property position for SPC-15. The company is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. Its therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system diseases.
Silo Pharma’s portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. The company’s research is conducted in collaboration with leading universities and laboratories.
For investors, the patent allowance could signal progress in bringing a novel PTSD treatment to market, potentially addressing a significant unmet medical need. PTSD affects millions of people worldwide, and current treatment options are limited. SPC-15’s intranasal delivery may offer a more convenient and effective approach, though further clinical trials are required.
The news may impact the biopharmaceutical industry by highlighting the importance of intellectual property in developing new therapies for psychiatric disorders. Silo Pharma’s expanded patent portfolio could enhance its competitive position and attract partnership or licensing opportunities.
To view the full press release, visit https://ibn.fm/Hh4Z6. For more information about BioMedWire, visit https://www.BioMedWire.com.
